3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Melanoma
3
Lung Neoplasms
3
Colitis
3
Urogenital Neoplasms
2
Solid Carcinoma
2
Diarrhea
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Gastrointestinal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Cyclophosphamide
13
pembrolizumab
8
Brentuximab Vedotin
8
fludarabine
7
Nivolumab
7
Whole-Body Irradiation
6
Specimen Handling
6
Mycophenolic Acid
6
Gemcitabine
6
Etoposide
6
Doxorubicin
6
Dacarbazine
6
fludarabine phosphate
5
Vinblastine
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Dexamethasone
5
Stem Cell Transplantation
4
Cytarabine
4
Vinorelbine
3
Tacrolimus
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
Carmustine
3
Blood Specimen Collection
3
thymoglobulin
2
polatuzumab vedotin
2
pegylated granulocyte colony-stimulating factor
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hodgkin Disease
×
Fecal Microbiota Transplantation
×
Clear all
NCT04935684
2023-03-01
TMF-Allo
University Hospital, Clermont-Ferrand
Phase 2
Recruiting
150 enrolled